State Street’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $304K | Hold |
26,453
| – | – | ﹤0.01% | 3714 |
|
|
2026
Q1 | $125K | Hold |
26,453
| – | – | ﹤0.01% | 3989 |
|
|
2025
Q4 | $479K | Buy |
26,453
+1,200
| +5% | +$17.9K | ﹤0.01% | 3694 |
|
|
2025
Q3 | $362K | Hold |
25,253
| – | – | ﹤0.01% | 3733 |
|
|
2025
Q2 | $195K | Hold |
25,253
| – | – | ﹤0.01% | 3844 |
|
|
2025
Q1 | $150K | Hold |
25,253
| – | – | ﹤0.01% | 3890 |
|
|
2024
Q4 | $336K | Buy |
25,253
+2,900
| +13% | +$30.6K | ﹤0.01% | 3729 |
|
|
2024
Q3 | $182K | Buy |
22,353
+7,680
| +52% | +$65.8K | ﹤0.01% | 3841 |
|
|
2024
Q2 | $125K | Sell |
14,673
-84,889
| -85% | -$1.28M | ﹤0.01% | 3945 |
|
|
2024
Q1 | $1.73M | Sell |
99,562
-11,806
| -11% | -$210K | ﹤0.01% | 3324 |
|
|
2023
Q4 | $1.43M | Buy |
111,368
+10,461
| +10% | +$244K | ﹤0.01% | 3401 |
|
|
2023
Q3 | $3.73M | Sell |
100,907
-775
| -0.8% | -$34.5K | ﹤0.01% | 3073 |
|
|
2023
Q2 | $4.09M | Sell |
101,682
-227,817
| -69% | -$12.9M | ﹤0.01% | 3092 |
|
|
2023
Q1 | $23.9M | Buy |
329,499
+23,509
| +8% | +$2.28M | ﹤0.01% | 2104 |
|
|
2022
Q4 | $25.1M | Sell |
305,990
-17,904
| -6% | -$1.87M | ﹤0.01% | 2078 |
|
|
2022
Q3 | $30.6M | Buy |
323,894
+75,027
| +30% | +$8.43M | ﹤0.01% | 1933 |
|
|
2022
Q2 | $48.5M | Sell |
248,867
-2,078
| -0.8% | -$339K | ﹤0.01% | 1661 |
|
|
2022
Q1 | $58.3M | Buy |
250,945
+77,977
| +45% | +$24.8M | ﹤0.01% | 1664 |
|
|
2021
Q4 | $68.1M | Buy |
172,968
+21,732
| +14% | +$9.15M | ﹤0.01% | 1592 |
|
|
2021
Q3 | $67.7M | Sell |
151,236
-23,638
| -14% | -$8.47M | ﹤0.01% | 1581 |
|
|
2021
Q2 | $68M | Sell |
174,874
-1,637
| -0.9% | -$584K | ﹤0.01% | 1615 |
|
|
2021
Q1 | $63.4M | Buy |
176,511
+57,133
| +48% | +$25.3M | ﹤0.01% | 1568 |
|
|
2020
Q4 | $58.6M | Sell |
119,378
-9,864
| -8% | -$4.55M | ﹤0.01% | 1546 |
|
|
2020
Q3 | $41.9M | Sell |
129,242
-1,392
| -1% | -$474K | ﹤0.01% | 1587 |
|
|
2020
Q2 | $47.6M | Buy |
130,634
+40,806
| +45% | +$10.3M | ﹤0.01% | 1494 |
|
|
2020
Q1 | $19.1M | Buy |
89,828
+1,809
| +2% | +$574K | ﹤0.01% | 1863 |
|
|
2019
Q4 | $36.2M | Sell |
88,019
-16,232
| -16% | -$5.6M | ﹤0.01% | 1744 |
|
|
2019
Q3 | $36.8M | Buy |
104,251
+11,625
| +13% | +$4.34M | ﹤0.01% | 1655 |
|
|
2019
Q2 | $46.6M | Buy |
92,626
+24,865
| +37% | +$17.6M | ﹤0.01% | 1533 |
|
|
2019
Q1 | $67.3M | Buy |
67,761
+372
| +0.6% | +$346K | 0.01% | 1269 |
|
|
2018
Q4 | $58.5M | Sell |
67,389
-16,840
| -20% | -$15.6M | 0.01% | 1262 |
|
|
2018
Q3 | $87.1M | Buy |
84,229
+209
| +0.2% | +$204K | 0.01% | 1161 |
|
|
2018
Q2 | $77.2M | Buy |
84,020
+3,697
| +5% | +$3.97M | 0.01% | 1215 |
|
|
2018
Q1 | $78.3M | Buy |
80,323
+62,570
| +352% | +$57M | 0.01% | 1138 |
|
|
2017
Q4 | $8.03M | Buy |
17,753
+511
| +3% | +$189K | ﹤0.01% | 2562 |
|
|
2017
Q3 | $7.14M | Buy |
17,242
+284
| +2% | +$107K | ﹤0.01% | 2608 |
|
|
2017
Q2 | $5.94M | Sell |
16,958
-7,633
| -31% | -$2.94M | ﹤0.01% | 2658 |
|
|
2017
Q1 | $12.6M | Buy |
24,591
+570
| +2% | +$236K | ﹤0.01% | 2243 |
|
|
2016
Q4 | $8.53M | Buy |
24,021
+9,262
| +63% | +$3.92M | ﹤0.01% | 2422 |
|
|
2016
Q3 | $7.89M | Buy |
14,759
+559
| +4% | +$304K | ﹤0.01% | 2312 |
|
|
2016
Q2 | $8M | Buy |
14,200
+3,530
| +33% | +$1.69M | ﹤0.01% | 2340 |
|
|
2016
Q1 | $5.08M | Sell |
10,670
-13,397
| -56% | -$6.03M | ﹤0.01% | 2536 |
|
|
2015
Q4 | $15.9M | Sell |
24,067
-6,871
| -22% | -$5.2M | ﹤0.01% | 1881 |
|
|
2015
Q3 | $24.3M | Buy |
30,938
+23,304
| +305% | +$28.4M | ﹤0.01% | 1631 |
|
|
2015
Q2 | $10.1M | Buy |
7,634
+4,770
| +167% | +$5.47M | ﹤0.01% | 2257 |
|
|
2015
Q1 | $2.97M | Buy |
2,864
+1,345
| +89% | +$889K | ﹤0.01% | 2851 |
|
|
2014
Q4 | $1.01M | Buy |
+1,519
| New | +$928K | ﹤0.01% | 3258 |
|
Other funds holding ATRA
VCM
SCA
VFT
State Street's ATRA Position: Q2 2026 in Review
State Street held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 26,453 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #3714.
State Street first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $87.1M in Q3 2018. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- State Street held 26,453 shares of Atara Biotherapeutics worth $304K as of Q2 2026.
- State Street left its Atara Biotherapeutics share count unchanged in Q2 2026.
- Atara Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3714 holding.
- State Street first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
- State Street's Atara Biotherapeutics position peaked at $87.1M in Q3 2018.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.